Temat: "HIV-1" - OpacWWW - Prolib Integro

Skocz do pozycji: 1.

Tytuł:: The cell biology of HIV-1 latency and rebound.
Autorzy:: Mbonye U; Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA. .
Karn J; Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA. .
Źródło:: Retrovirology [Retrovirology] 2024 Apr 05; Vol. 21 (1), pp. 6. Date of Electronic Publication: 2024 Apr 05.
Typ publikacji:: Journal Article; Review
MeSH Terms:: HIV-1*/physiology
HIV Infections*
Humans ; Virus Latency ; Positive Transcriptional Elongation Factor B/genetics ; Positive Transcriptional Elongation Factor B/metabolism ; CD4-Positive T-Lymphocytes ; Proviruses/metabolism ; Virus Activation

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Modeling and Analysis of HIV-1 Pol Polyprotein as a Case Study for Predicting Large Polyprotein Structures.
Autorzy:: Hao M; Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Imamichi T; Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Chang W; Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Feb 02; Vol. 25 (3). Date of Electronic Publication: 2024 Feb 02.
Typ publikacji:: Journal Article
MeSH Terms:: HIV Infections*/drug therapy
HIV-1*/genetics
HIV-1*/metabolism
pol Gene Products, Human Immunodeficiency Virus*/chemistry
Humans ; Gene Products, pol/genetics ; Gene Products, pol/metabolism ; HIV Protease/genetics ; HIV Protease/metabolism ; Polyproteins/genetics ; RNA-Directed DNA Polymerase/metabolism

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies.
Autorzy:: Walmsley S; University Health Network, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada.
Smith DE; Albion Centre, 150 Albion Street, Surry Hills NSW 2010, Sydney, Australia.
Górgolas M; Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Av. de los Reyes Católicos, 2, 28040, Madrid, Spain.
Cahn PE; Fundación Huésped, Dr. Carlos A. Gianantonio 3932, C1204 CABA, Buenos Aires, Argentina.
Lutz T; Infektiologikum, Stresemannallee 3, 60596, Frankfurt am Main, Frankfurt, Germany.
Lacombe K; Hôpital Saint-Antoine, 184 Rue du Faubourg Saint-Antoine, 75012, Paris, France.
Kumar PN; Georgetown University Medical Center, 4000 Reservoir Road, NW, Washington, DC, 20057, USA.
Wynne B; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC, 27701, USA.
Grove R; GSK, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK.
Bontempo G; ViiV Healthcare, 36 E Industrial Road, Branford, CT, 06405, USA.
Moodley R; ViiV Healthcare, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK.
Okoli C; ViiV Healthcare, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK.
Kisare M; ViiV Healthcare, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK. .
Jones B; ViiV Healthcare, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK.
Clark A; ViiV Healthcare, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK.
Ait-Khaled M; ViiV Healthcare, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK.
Źródło:: AIDS research and therapy [AIDS Res Ther] 2024 Mar 21; Vol. 21 (1), pp. 17. Date of Electronic Publication: 2024 Mar 21.
Typ publikacji:: Journal Article
MeSH Terms:: HIV-1*
Anti-HIV Agents*/adverse effects
HIV Infections*/drug therapy
HIV Seropositivity*/drug therapy
Oxazines*
Piperazines*
Pyridones*
Humans ; Male ; Female ; Lamivudine/adverse effects ; Heterocyclic Compounds, 3-Ring/adverse effects ; Anti-Retroviral Agents/therapeutic use ; RNA

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: HIV-1 Vpr Functions in Primary CD4 T Cells.
Autorzy:: Vanegas-Torres CA; Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Schindler M; Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Źródło:: Viruses [Viruses] 2024 Mar 09; Vol. 16 (3). Date of Electronic Publication: 2024 Mar 09.
Typ publikacji:: Journal Article; Review
MeSH Terms:: HIV-1*/genetics
HIV Seropositivity*
HIV Infections*/metabolism
Humans ; T-Lymphocytes/metabolism ; vpr Gene Products, Human Immunodeficiency Virus/genetics ; vpr Gene Products, Human Immunodeficiency Virus/metabolism ; CD4-Positive T-Lymphocytes/metabolism

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies.
Autorzy:: Underwood M; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Urbaityte R; GSK, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.
Wang R; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Horton J; Parexel, 2520 Meridian Parkway, Durham, NC 27713, USA.
Oyee J; GSK, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.
Wynne B; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Fox D; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Jones B; ViiV Healthcare, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.
Man C; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Sievers J; ViiV Healthcare, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.
Źródło:: Viruses [Viruses] 2024 Mar 06; Vol. 16 (3). Date of Electronic Publication: 2024 Mar 06.
Typ publikacji:: Journal Article
MeSH Terms:: HIV Infections*/drug therapy
Anti-HIV Agents*/therapeutic use
HIV-1*
HIV Seropositivity*
Oxazines*
Piperazines*
Pyridones*
Adult ; Humans ; Lamivudine/therapeutic use ; Emtricitabine/therapeutic use ; Tenofovir/therapeutic use ; Drug Therapy, Combination ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Viral Load ; Virus Replication

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: The origin, dissemination, and molecular networks of HIV-1 CRF65_cpx strain in Hainan Island, China.
Autorzy:: Yu D; Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Colleges and Universities Key Laboratory of Prevention and Control of Highly Prevalent Diseases, School of Public Health, Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, China.; International School of Public Health and One Health, Hainan Medical University, 3 Xueyuan Road, Haikou, 571199, China.
Zhu K; Prevention and Treatment Department, the Fifth People's Hospital of Hainan Province, 3 Xueyuan Road, Haikou, 570102, China.
Li M; Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Colleges and Universities Key Laboratory of Prevention and Control of Highly Prevalent Diseases, School of Public Health, Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, China.
Zhang F; Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Colleges and Universities Key Laboratory of Prevention and Control of Highly Prevalent Diseases, School of Public Health, Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, China.
Yang Y; Guangxi Engineering Center for Organoids and Organ-on-chips of Highly Pathogenic Microbial Infections & Biosafety laboratory, Life Science Institute, Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, China.
Lu C; International School of Public Health and One Health, Hainan Medical University, 3 Xueyuan Road, Haikou, 571199, China.
Zhong S; Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Colleges and Universities Key Laboratory of Prevention and Control of Highly Prevalent Diseases, School of Public Health, Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, China.
Qin C; Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Colleges and Universities Key Laboratory of Prevention and Control of Highly Prevalent Diseases, School of Public Health, Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, China.
Lan Y; Guangxi medical university oncology school, 22 Shuangyong Road, Nanning, 530021, China.
Yu J; The First Clinical Medical College, Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, China.
Petersen JD; International School of Public Health and One Health, Hainan Medical University, 3 Xueyuan Road, Haikou, 571199, China.; Research Unit for General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.; Research Unit for General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Jiang J; Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Colleges and Universities Key Laboratory of Prevention and Control of Highly Prevalent Diseases, School of Public Health, Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, China.; Guangxi Engineering Center for Organoids and Organ-on-chips of Highly Pathogenic Microbial Infections & Biosafety laboratory, Life Science Institute, Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, China.
Liang H; Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Colleges and Universities Key Laboratory of Prevention and Control of Highly Prevalent Diseases, School of Public Health, Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, China. .; Guangxi Engineering Center for Organoids and Organ-on-chips of Highly Pathogenic Microbial Infections & Biosafety laboratory, Life Science Institute, Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, China. .
Ye L; Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Colleges and Universities Key Laboratory of Prevention and Control of Highly Prevalent Diseases, School of Public Health, Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, China. .; Guangxi Engineering Center for Organoids and Organ-on-chips of Highly Pathogenic Microbial Infections & Biosafety laboratory, Life Science Institute, Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, China. .
Liang B; Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Colleges and Universities Key Laboratory of Prevention and Control of Highly Prevalent Diseases, School of Public Health, Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, China. .; Guangxi Engineering Center for Organoids and Organ-on-chips of Highly Pathogenic Microbial Infections & Biosafety laboratory, Life Science Institute, Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, China. .
Źródło:: BMC infectious diseases [BMC Infect Dis] 2024 Mar 01; Vol. 24 (1), pp. 269. Date of Electronic Publication: 2024 Mar 01.
Typ publikacji:: Journal Article
MeSH Terms:: HIV-1*/genetics
HIV Infections*
Sexual and Gender Minorities*
HIV Seropositivity*
Male ; Middle Aged ; Humans ; Adult ; Adolescent ; Young Adult ; Female ; Homosexuality, Male ; Bayes Theorem ; Phylogeny ; China/epidemiology

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Molecular Dynamics Investigation of Lipid-Specific Interactions with a Fusion Peptide.
Autorzy:: Heller WT; Neutron Scattering Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA.
Źródło:: Biomolecules [Biomolecules] 2024 Feb 27; Vol. 14 (3). Date of Electronic Publication: 2024 Feb 27.
Typ publikacji:: Journal Article
MeSH Terms:: Lipid Bilayers*/chemistry
HIV-1*/metabolism
Molecular Dynamics Simulation ; HIV Envelope Protein gp41/chemistry ; Peptides/chemistry

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: A pilot investigation of the association between HIV-1 Vpr amino acid sequence diversity and the tryptophan-kynurenine pathway as a potential mechanism for neurocognitive impairment.
Autorzy:: Asia LK; Human Metabolomics, North-West University, Potchefstroom, South Africa.
Van Vuren EJ; Hypertension in Africa Research Team (HART), North-West University, Potchefstroom, South Africa.; South African Medical Research Council, Unit for Hypertension and Cardiovascular Disease, North-West University, Potchefstroom, South Africa.
Lindeque Z; Human Metabolomics, North-West University, Potchefstroom, South Africa.
Williams ME; Human Metabolomics, North-West University, Potchefstroom, South Africa. .
Źródło:: Virology journal [Virol J] 2024 Feb 23; Vol. 21 (1), pp. 47. Date of Electronic Publication: 2024 Feb 23.
Typ publikacji:: Journal Article
MeSH Terms:: HIV-1*/genetics
HIV-1*/metabolism
HIV Infections*/complications
Gene Products, vpr*
HIV Seropositivity*
Humans ; Tryptophan/metabolism ; Kynurenine/metabolism ; Amino Acid Sequence ; Chromatography, Liquid ; Pilot Projects ; Receptors, Urokinase Plasminogen Activator ; Tandem Mass Spectrometry ; Inflammation

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Immunoinformatic Identification of Multiple Epitopes of gp120 Protein of HIV-1 to Enhance the Immune Response against HIV-1 Infection.
Autorzy:: Habib A; Laboratory of Molecular Immunology, State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200433, China.
Liang Y; Laboratory of Molecular Immunology, State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200433, China.
Xu X; Laboratory of Molecular Immunology, State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200433, China.
Zhu N; Laboratory of Molecular Immunology, State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200433, China.; Institute of Biomedical Sciences, School of Life Sciences, Fudan University, Shanghai 200438, China.
Xie J; Laboratory of Molecular Immunology, State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200433, China.
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Feb 19; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 19.
Typ publikacji:: Journal Article
MeSH Terms:: Epitopes*
HIV Infections*
HIV-1*
Vaccines*
Humans ; Amino Acid Sequence ; Computational Biology ; Immunity ; Immunoinformatics ; Molecular Docking Simulation ; Peptides ; Vaccines, Subunit

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: PTEN Mediates the Silencing of Unintegrated HIV-1 DNA.
Autorzy:: Phan AT; Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Zhu Y; Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Źródło:: Viruses [Viruses] 2024 Feb 14; Vol. 16 (2). Date of Electronic Publication: 2024 Feb 14.
Typ publikacji:: Journal Article
MeSH Terms:: HIV-1*/physiology
NF-kappa B*/metabolism
DNA, Viral/genetics ; DNA, Viral/metabolism ; Phosphatidylinositol 3-Kinases/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Phosphoric Monoester Hydrolases/metabolism ; Proto-Oncogene Proteins c-akt/genetics ; Proto-Oncogene Proteins c-akt/metabolism ; Transcription Factor AP-1/metabolism ; Transcription, Genetic ; Humans

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Macrophages: Key Cellular Players in HIV Infection and Pathogenesis.
Autorzy:: Woottum M; Institut Cochin, Inserm U1016, CNRS UMR-8104, Université Paris Cité, 75014 Paris, France.
Yan S; Institut Cochin, Inserm U1016, CNRS UMR-8104, Université Paris Cité, 75014 Paris, France.
Sayettat S; Institut Cochin, Inserm U1016, CNRS UMR-8104, Université Paris Cité, 75014 Paris, France.
Grinberg S; CNRS UMR-8601, Université Paris Cité, 75006 Paris, France.
Cathelin D; CNRS UMR-8601, Université Paris Cité, 75006 Paris, France.
Bekaddour N; CNRS UMR-8601, Université Paris Cité, 75006 Paris, France.
Herbeuval JP; CNRS UMR-8601, Université Paris Cité, 75006 Paris, France.
Benichou S; Institut Cochin, Inserm U1016, CNRS UMR-8104, Université Paris Cité, 75014 Paris, France.
Źródło:: Viruses [Viruses] 2024 Feb 13; Vol. 16 (2). Date of Electronic Publication: 2024 Feb 13.
Typ publikacji:: Journal Article; Review
MeSH Terms:: HIV Infections*
Simian Immunodeficiency Virus*
HIV-1*/physiology
HIV Seropositivity*
Humans ; Animals ; Mice ; Macrophages ; Inflammation ; CD4-Positive T-Lymphocytes ; Virus Latency ; Virus Replication

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: HIV-1 Proviral Genome Engineering with CRISPR-Cas9 for Mechanistic Studies.
Autorzy:: Hyder U; Department of Microbiology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Shukla A; Department of Microbiology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Challa A; Department of Microbiology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
D'Orso I; Department of Microbiology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Źródło:: Viruses [Viruses] 2024 Feb 13; Vol. 16 (2). Date of Electronic Publication: 2024 Feb 13.
Typ publikacji:: Journal Article
MeSH Terms:: HIV-1*/genetics
HIV Infections*
Humans ; Proviruses/genetics ; CRISPR-Cas Systems ; Virus Latency/genetics

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Stable expression of HIV-1 MPER extended epitope on the surface of the recombinant probiotic bacteria Escherichia Coli Nissle 1917 using CRISPR/Cas9.
Autorzy:: Ninyio N; School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Schmitt K; School of Science and Technology, Life Science Center, Örebro University, Örebro, Sweden.; Institute of Virology, Saarland University Medical Center, 66421, Homburg, Germany.
Sergon G; School of Science and Technology, Life Science Center, Örebro University, Örebro, Sweden.
Nilsson C; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.; Department of Microbiology, Public Health Agency of Sweden, Solna, Sweden.
Andersson S; School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.; Department of Public Health Analysis and Data Management, Unit for Vaccination Programmes, Public Health Agency of Sweden, Solna, Sweden.
Scherbak N; School of Science and Technology, Life Science Center, Örebro University, Örebro, Sweden. .
Źródło:: Microbial cell factories [Microb Cell Fact] 2024 Feb 04; Vol. 23 (1), pp. 39. Date of Electronic Publication: 2024 Feb 04.
Typ publikacji:: Journal Article
MeSH Terms:: HIV-1*/genetics
Vaccines*
Animals ; Humans ; Epitopes ; Escherichia coli/genetics ; CRISPR-Cas Systems ; HIV Antibodies

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: A Canadian Survey of Research on HIV-1 Latency-Where Are We Now and Where Are We Heading?
Autorzy:: Abdalla AL; HIV-1 RNA Trafficking Laboratory, Lady Davis Institute at the Jewish General Hospital, Montreal, QC H3T 1E2, Canada.; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada.
Guajardo-Contreras G; HIV-1 RNA Trafficking Laboratory, Lady Davis Institute at the Jewish General Hospital, Montreal, QC H3T 1E2, Canada.; Department of Medicine, McGill University, Montreal, QC H4A 3J1, Canada.
Mouland AJ; HIV-1 RNA Trafficking Laboratory, Lady Davis Institute at the Jewish General Hospital, Montreal, QC H3T 1E2, Canada.; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada.; Department of Medicine, McGill University, Montreal, QC H4A 3J1, Canada.
Źródło:: Viruses [Viruses] 2024 Feb 01; Vol. 16 (2). Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:: Journal Article; Review
MeSH Terms:: HIV-1*
HIV Infections*/drug therapy
HIV Infections*/metabolism
HIV Seropositivity*
Humans ; Virus Latency ; CD4-Positive T-Lymphocytes/metabolism ; Canada ; Virus Activation

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: A macrophage-cell model of HIV latency reveals the unusual importance of the bromodomain axis.
Autorzy:: Kisaka JK; Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, 63110, USA.
Rauch D; Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, 63110, USA.
Griffith M; Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, 63110, USA.; McDonnell Genome Institute, Washington University School of Medicine in St. Louis, St. Louis, MO, 63108, USA.
Kyei GB; Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, 63110, USA. .; Department of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, MO, 63110, USA. .; Department of Virology, College of Health Sciences, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana. .; Medical and Scientific Research Center, University of Ghana Medical Center, Accra, Ghana. .
Źródło:: Virology journal [Virol J] 2024 Apr 05; Vol. 21 (1), pp. 80. Date of Electronic Publication: 2024 Apr 05.
Typ publikacji:: Journal Article
MeSH Terms:: HIV Infections*
HIV-1*/genetics
Humans ; Virus Latency/genetics ; Virus Activation ; Transcription Factors ; Nuclear Proteins ; Macrophages ; CD4-Positive T-Lymphocytes ; Bromodomain Containing Proteins ; Cell Cycle Proteins

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1.
Autorzy:: Cassidy T; School of Mathematics, University of Leeds, Leeds, United Kingdom.
Stephenson KE; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.; Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Barouch DH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.; Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.
Perelson AS; Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.
Źródło:: PLoS computational biology [PLoS Comput Biol] 2024 Mar 29; Vol. 20 (3), pp. e1011518. Date of Electronic Publication: 2024 Mar 29 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: HIV Infections*
HIV-1*
Humans ; Antibodies, Neutralizing/therapeutic use ; Broadly Neutralizing Antibodies ; HIV Antibodies ; Models, Theoretical

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Caregivers of children with HIV in Botswana prefer monthly IV Broadly Neutralizing Antibodies (bNAbs) to daily oral ART.
Autorzy:: Sakoi-Mosetlhi M; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Ajibola G; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Haghighat R; Harvard Medical School, Boston, Massachusetts, United States of America.
Batlang O; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Maswabi K; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Pretorius-Holme M; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Powis KM; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.; Harvard Medical School, Boston, Massachusetts, United States of America.; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.; Departments of Internal Medicine and Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Lockman S; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.; Ragon Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts, United States of America.
Makhema J; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Litcherfeld M; Ragon Institute of Mass General, MIT, and Harvard, Cambridge, Massachusetts, United States of America.
Kuritzkes DR; Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
Shapiro R; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Źródło:: PloS one [PLoS One] 2024 Mar 27; Vol. 19 (3), pp. e0299942. Date of Electronic Publication: 2024 Mar 27 (Print Publication: 2024).
Typ publikacji:: Evaluation Study; Journal Article
MeSH Terms:: HIV Infections*
HIV-1*
Child ; Female ; Humans ; Antibodies, Neutralizing ; Botswana ; Broadly Neutralizing Antibodies/therapeutic use ; Caregivers ; HIV Antibodies/therapeutic use ; Mothers

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
Autorzy:: Moodie Z; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Andersen-Nissen E; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa.
Grunenberg N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Dintwe OB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.; Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa.
Omar FL; Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa.
Kee JJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Bekker LG; Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Laher F; Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Naicker N; Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa; and Department of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa.
Jani I; Instituto Nacional de Saude, Maputo, Mozambique.
Mgodi NM; Clinical Trials Research Centre, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Hunidzarira P; Clinical Trials Research Centre, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.
Sebe M; Aurum Institute, Tembisa, Gauteng, South Africa.
Miner MD; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Polakowski L; DAIDS, NIAID, NIH, Bethesda, Maryland, United States of America.
Ramirez S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Nebergall M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Takuva S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Sikhosana L; Hutchinson Centre Research Institute of South Africa, Johannesburg, South Africa.
Heptinstall J; Department of Surgery, Duke University, Durham, North Carolina, United States of America.
Seaton KE; Department of Surgery, Duke University, Durham, North Carolina, United States of America.
De Rosa S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Diazgranados CA; Formerly Sanofi-Pasteur, Swiftwater, Pennsylvania, Pennsylvania, United States of America.
Koutsoukos M; GSK, Wavre, Belgium.
Van Der Meeren O; Previously GSK, Rixensart, Belgium.
Barnett SW; Bill & Melinda Gates Foundation, Seattle, Washington, United States of America.
Kanesa-Thasan N; Formerly GSK, Rockville, Maryland, United States of America.
Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Tomaras GD; Department of Surgery, Duke University, Durham, North Carolina, United States of America.
McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
Mngadi K; Aurum Institute, Tembisa, Gauteng, South Africa.
Goepfert P; Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Corporate Authors:: HVTN 107 Protocol Team
Źródło:: PLoS medicine [PLoS Med] 2024 Mar 19; Vol. 21 (3), pp. e1004360. Date of Electronic Publication: 2024 Mar 19 (Print Publication: 2024).
Typ publikacji:: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms:: AIDS Vaccines*/adverse effects
Alum Compounds*
HIV Infections*/prevention & control
HIV-1*
Polysorbates*
Squalene*
Adult ; Humans ; Adjuvants, Immunologic ; HIV Antibodies ; Immunogenicity, Vaccine ; Immunoglobulin A ; Immunoglobulin G ; Vaccines, Combined ; Vaccines, Synthetic

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Bioinformatics Insights on Viral Gene Expression Transactivation: From HIV-1 to SARS-CoV-2.
Autorzy:: Patarca R; ACCESS Health International, 384 West Lane, Ridgefield, CT 06877, USA.; Feinstein Institutes for Medical Research, 350 Community Dr, Manhasset, NY 11030, USA.
Haseltine WA; ACCESS Health International, 384 West Lane, Ridgefield, CT 06877, USA.; Feinstein Institutes for Medical Research, 350 Community Dr, Manhasset, NY 11030, USA.
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Mar 16; Vol. 25 (6). Date of Electronic Publication: 2024 Mar 16.
Typ publikacji:: Journal Article
MeSH Terms:: HIV-1*/physiology
COVID-19*/genetics
Humans ; SARS-CoV-2/genetics ; SARS-CoV-2/metabolism ; Transcriptional Activation ; HIV Long Terminal Repeat ; Gene Products, tat/genetics ; Lentivirus/genetics ; Gene Expression ; tat Gene Products, Human Immunodeficiency Virus/genetics ; tat Gene Products, Human Immunodeficiency Virus/metabolism ; RNA, Viral/metabolism

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon.
Autorzy:: Nzengui-Nzengui GF; Département de Bactériologie- Virologie, Laboratoire National de Référence IST/VIH/Sida, Université des Sciences de la Santé, Libreville, Gabon.
Mourembou G; Département de Bactériologie- Virologie, Laboratoire National de Référence IST/VIH/Sida, Université des Sciences de la Santé, Libreville, Gabon.
M'boyis-Kamdem H; Département de Bactériologie- Virologie, Laboratoire National de Référence IST/VIH/Sida, Université des Sciences de la Santé, Libreville, Gabon.
Kombila-Koumavor AC; Département de Bactériologie- Virologie, Laboratoire National de Référence IST/VIH/Sida, Université des Sciences de la Santé, Libreville, Gabon.
Ndjoyi-Mbiguino A; Département de Bactériologie- Virologie, Laboratoire National de Référence IST/VIH/Sida, Université des Sciences de la Santé, Libreville, Gabon. .
Źródło:: BMC infectious diseases [BMC Infect Dis] 2024 Mar 14; Vol. 24 (1), pp. 316. Date of Electronic Publication: 2024 Mar 14.
Typ publikacji:: Journal Article
MeSH Terms:: Anti-HIV Agents*/therapeutic use
Anti-HIV Agents*/pharmacology
HIV Infections*/drug therapy
HIV-1*/genetics
Male ; Humans ; Female ; Reverse Transcriptase Inhibitors/therapeutic use ; HIV Protease/genetics ; Gabon ; Anti-Retroviral Agents/therapeutic use ; Protease Inhibitors/therapeutic use ; Mutation ; Drug Resistance, Viral/genetics

Czasopismo naukowe

Zmień widok

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""HIV-1"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język

Rok publikacji